HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery

Connie L Celum1,2,3§, Sinead Delany-Moretlwe4, Jared M Baeten1,2,3, Ariane van der Straten5, Sybil Hosek6, Elizabeth A Bukusi1,7,8, Margaret McConnell9, Ruanne V Barnabas1,2,3 and Linda-Gail Bekker10

§Corresponding author: Connie L Celum, Department of Global Health, International Clinical Research Center, University of Washington, 325 Ninth Avenue, Box 359927, Seattle, WA 98104, USA. Tel: +1 206 520 3800. (ccelum@uw.edu)

Abstract
Introduction: Adolescent girls and young women (AGYW) in Africa have high HIV incidence despite scale-up of HIV testing and HIV treatment. Placebo-controlled trials of tenofovir-based pre-exposure prophylaxis (PrEP) in diverse populations demonstrated that PrEP works with close to 100% effectiveness if taken with high, but not perfect, adherence. Divergent efficacy estimates among African AGYW led to demonstration and implementation projects to better understand motivations for HIV prevention, uptake, adherence and persistence to PrEP. To inform PrEP programmes, the design and initial findings from PrEP demonstration projects for AGYW are reviewed.

Discussion: Early lessons from PrEP implementation projects among young African women include: (1) awareness and demand creation with positive messaging about the benefits of PrEP are critical to motivate AGYW to consider this novel prevention technology and to foster awareness among peers, partners, parents and guardians to support AGYW’s effective PrEP use; (2) PrEP initiation is high in projects that are integrating PrEP into youth-friendly clinics, family planning clinics and mobile clinics; (3) young African women at risk are initiating PrEP, based on behavioural characteristics, history of intimate partner violence, depression and 30% prevalence of chlamydia and/or gonorrhoea; (4) provision of youth-friendly PrEP delivery programmes that integrate reproductive health services, including contraception and the diagnosis and treatment of sexually transmitted infections, increase health impact; (5) messages that emphasize the necessity for high adherence while at potential risk of HIV exposure and support strategies that addresses AGYW’s adherence challenges are essential; and, (6) a substantial proportion of AGYW do not persist with PrEP, and strategies are needed to help AGYW assess their ongoing need, motivation and challenges with persisting with PrEP.

Conclusions: PrEP is feasible to implement in integrated reproductive health service delivery models to reach African AGYW. While PrEP demonstration projects indicate that women with behavioural risks and high rates of sexually transmitted diseases are initiating PrEP, effective strategies to support AGYW’s adherence and persistence with PrEP are needed. Lessons learned from oral PrEP delivery, a novel first generation HIV prevention product, are relevant to longer-acting and less adherence-dependent strategies which are currently in clinical trials.

Keywords: HIV prevention; pre-exposure prophylaxis; adolescents; young women; Africa
couples in the Partners PrEP study where adherence was 80% [10]. In contrast, in the VOICE and FEM-PrEP trials, young women were not protected, most of whom had a partner of unknown HIV status, and among whom only 25% had detectable tenofovir levels [4,5]. In VOICE, young women (<25 years) were at greatest risk for HIV infection and less likely to adhere. Nevertheless, a subsequent meta-analysis of all PrEP trials including women estimated 61% PrEP efficacy among women with > 75% adherence based on drug levels [11].

The results of the VOICE and FEM-PrEP trials led to concerns that young African women did not recognize their risk, would lack motivation or be unable to adhere to daily pill-taking for HIV prevention. Notably, the quantitative measure of risk perception in these trials was based on a single question, which may be insufficient for understanding how women viewed their risk. In contrast, in-depth interviews indicated that women often recognized their risk [12]. Socio-behavioural research during and following the VOICE and FEM-PrEP trials found that participants had altruistic motivations for joining the studies but were balancing this against the practical realities of their daily lives. In the African context where access to quality care and resources is limited, participants desired access to non-judgemental, confidential clinical services, counselling support, and contraception. HIV and sexually transmitted infection (STI) testing and treatment which were provided by the trial sites [13,14]. Small study reimbursements (<$15) helped participants meet transport costs and other needs [14-16].

Women faced many challenges in these studies, including their concerns about receiving a placebo or an investigational drug of unknown efficacy and potential side effects [17-20]. “Present bias” is the tendency to disproportionately focus on rewards in the present to the detriment of achieving desired long-term outcomes [21-23], and is a strong motivator in AGYW, which could have discouraged committed product usage. Qualitative research suggests that rumours and peers’ comments about not using their study products influenced participants’ adherence. Indeed, a daily pill regimen can be both logistically and emotionally burdensome (as it may remind women about HIV or IPV) [16]. When offered HIV prevention alternatives through discrete choice experiments which assess hypothetical preferences and trade-offs between them, women prefer longer-acting and more adherence “forgiving” products, supporting the development of a range of PrEP delivery modalities – ring, injectable, implantable – from which young women can choose [38,40,41]. In parallel with development of formulations with less frequent dosing, it is important to learn about delivery and use of oral PrEP, a vanguard product.

2.2 Lessons about PrEP effectiveness from other populations

Open-label PrEP studies have demonstrated that risk perception and HIV prevention motivation might be less of a challenge than initially anticipated. Significantly higher effectiveness than efficacy was observed in open-label studies, including the PROUD study (immediate vs delayed open-label PrEP among men who have sex with men (MSM) attending sexual health clinics in the UK) [42] and HIV serodiscordant couples in the Partners Demo Project [43,44], which provided time-limited PrEP for HIV-uninfected partners until the HIV-positive partner was virally suppressed on antiretroviral therapy (ART). Similarly, effectiveness of the first longer acting PrEP product – the dapivirine ring – was higher in an open-label extension study than in the placebo-controlled efficacy trials [45].

Studies specific to adolescents and youth have provided useful and encouraging data. In the HPTN 067/ADAPT trial of daily, fixed intermittent or event-driven dosing among young women in Cape Town, adherence to daily PrEP was 75% and daily dosing provided the highest coverage of sex acts [46]. A US-based study of oral PrEP among MSM ages 15 to 17 (Adolescent Trials Network [ATN] 113) demonstrated that the majority had intracellular tenofovir-diphosphate (TFV-DP) levels commensurate with HIV protection (>700 fmol TFV-DP/punch) over the first three months [47], which decreased over the second six months when visits became quarterly. Similarly, the PlusPills study conducted in South Africa among adolescent boys and girls ages 15 to 19, found that PrEP was safe, acceptable and well-tolerated in this age group, but that adherence dropped in the second half of the study when visits were spaced quarterly instead of monthly [47]. In summary, open-label PrEP studies have demonstrated that risk perception, HIV prevention motivation, and time-bounded use of PrEP might be less of a challenge than initially anticipated, although strategies are needed to support PrEP adherence and persistence.

2.3 PrEP implementation for African young women: early lessons

In 2016, WHO recommended that PrEP be targeted to persons at “substantial” risk for HIV, defined as an annual HIV incidence of 3% or higher without PrEP [48], which includes AGYW in high burden geographies in Africa. Initial PrEP demonstration projects for African young women focused on supporting and studying adherence. Notably, the goal for oral PrEP use should not be perfect adherence but “prevention
Effective adherence with high adherence during periods of risk [49]. A number of PrEP implementation projects for African young women are studying PrEP uptake, adherence and persistence, and some projects will evaluate impact using a counterfactual estimate of HIV incidence without PrEP (Table 1). These projects have highlighted the challenges of implementing a novel prevention intervention prior to national guidelines in African countries, and thus in advance of provider training, with limited PrEP awareness and availability.

2.4 Demand creation for PrEP

The need for awareness and demand creation became clear early after launching PrEP demonstration projects for young African women, a population that typically accesses health services primarily for contraception. In the case of PrEP, demand creation involves clear, concise and compelling descriptions about PrEP and why women should be interested in it, especially in the context where there is very limited precedent for taking a pill purely for prevention, as most African AGYW use injectable rather than oral contraception. Importantly, antiretroviral use continues to have substantial stigma and AGYW consistently report concerns that others will think that they are HIV positive. Effective demand creation for PrEP creates awareness and motivates persons at risk of HIV to formulate their sexual health goals and motivations for HIV prevention.

Qualitative and ethnographic research was conducted to develop a demand creation strategy for PrEP among young women for the 3P (Partners, Perceptions and Pills) project in Cape Town, and found that pills are perceived as being for treatment rather than prevention and that emphasizing the positive benefits of PrEP in increasing confidence and empowerment would motivate AGYW to consider PrEP [54]. Feedback from young women in focus group discussions during development of a video and print materials recommended that demand creation materials show strong, aspirational and stylish women, message the positive benefits of PrEP in terms of young women’s empowerment, and include images of men [50]. Demand creation and communication materials about PrEP need to avoid perceptions that PrEP is only for women, and implications that women are responsible for HIV prevention. While 72% of women who viewed the brief motivational video expressed strong interest in PrEP, a minority enrolled soon after viewing the video and those who enrolled and initiated PrEP in the 3P study often needed to hear about PrEP from community outreach workers, community events, peers, and parents [50]. AGYW reported that it was difficult to be both a PrEP user and advocate if community, neighbours and significant others were unaware of it [51].

Despite the need for greater community awareness about PrEP, these projects have demonstrated that there is demand for PrEP when AGYW are educated about it, as indicated by >90% uptake in HPTN 082 (Table 2) [52]. Young women who are initiating PrEP in these demonstration projects are at risk, as measured by the very high rates of depression symptoms (almost 50%), history of IPV (20% to 50%), and 30% prevalence of gonorrhoea and chlamydia, most of which was asymptomatic [53]. These high rates of curable STIs in AGYW initiating PrEP highlight that syndromic case management is inadequate and needs to be replaced with etiologic STI testing, the cost of which has been a barrier to implementation. STI testing can be part of PrEP demand creation for AGYW, inform their risk perception and need for PrEP, and STI treatment can avoid adverse impacts on their fertility.

2.5 PrEP adherence and persistence

PrEP demonstration projects among African AGYW indicate the early drop off rates in the first few months after PrEP start are approximately 50%, with about 20% of AGYW restarting PrEP within six months in the POWER study [54]. Qualitative

| Study name and clinicaltrials.gov number | Population | N | Primary objectives |
|-----------------------------------------|------------|---|--------------------|
| PlusPills NCT03142256                    | 150 men and women 15 to 19 years, Soweto and Cape Town, South Africa | 150 | PrEP uptake (i.e. acceptance and initiation) and persistence (i.e. continuation) |
| EMPPOWER South African National Clinical Trials 4353 | Young women 16 to 24 years; Johannesburg South Africa and Mwanza, Tanzania | 431 | Effect of empowerment clubs on PrEP uptake and persistence |
| HPTN 082 NCT02732730                     | 427 women 16 to 21 years in Cape Town and Johannesburg, South Africa, and Harare, Zimbabwe | 427 | PrEP uptake, effect of drug level feedback on PrEP adherence, and modelled impact compared to a counterfactual HIV incidence estimate |
| 3P (Partners, Perception, Pills) NCT03142256 | 200 women 16 to 21 years in Cape Town, South Africa | 200 | Effect of incentives conditioned on adherence (i.e. objectively measured with drug levels) on subsequent PrEP adherence and persistence |
| POWER NCT03490058                        | 1504 women 16 to 21 years in Cape Town and Johannesburg, South Africa, and Kisumu, Kenya | 1504 | PrEP delivery models (mobile van, youth friendly clinic, family planning clinics) and cost-effectiveness |
| Community PrEP NCT03977181               | Young women 16 to 25 years in Buffalo City, Eastern Cape Province, South Africa | 640 | PrEP uptake, persistence and community models of delivery to promote persistence and adherence |
research is exploring whether this early stopping is related to AGYW experimenting with a novel idea, concerns about PrEP side effects, not liking or being able to take a pill a day, or reassessment of their sexual health goals. Encouragingly, several demonstration projects have shown higher adherence than in VOICE and FEM-PrEP based on drug levels; at the three month visit in HPTN 082 intracellular TFV-DP was detected in 84% of AGYW and 25% had high TFV-DP levels in the 3P study, 99% of participants had detectable tenofovir and 50% had high TFV-DP levels at three months [56].

Young persons are likely to need more PrEP adherence support and more frequent contact with health providers for effective PrEP use and persistence. It is important to build in flexibility into PrEP programs for refill timing, as AGYW may not use PrEP daily and may not come for refills until they are out of pills. One strategy to foster PrEP persistence is to integrate PrEP delivery and refills with other reproductive health services (e.g., every three month injectable contraception and STI testing), making clinic visits more salient and efficient.

Peer support is also important and can be fostered through PrEP clubs, which were well-attended and valued by two-thirds of participants in HPTN 082 [52]. Peer support has been shown to improve adherence in outpatients starting ART [57], and adolescents [58]. Group-based interventions for youth offer an effective way to implement intervention content while providing social support from peers, given the importance of peer opinion during adolescence and evidence that peer norms – peer-accepted or peer-rejected – are important in shaping adolescent behavior [62].

Table 2. Findings from pre-exposure prophylaxis (PrEP) implementation projects in African young women

| Observations from PrEP demonstration and delivery projects | Supporting data from PrEP projects |
|-----------------------------------------------------------|----------------------------------|
| Demand creation is needed, both prior to and after national guidelines and wider PrEP availability and knowledge about PrEP exist | High interest in PrEP after 90 second motivational video in Cape Town, supplemented with other educational and recruitment strategies [76] |
| AGYW at risk of HIV are initiating PrEP with high uptake | 90% to 95% PrEP uptake in EMPOWER, POWER [55,77] and HPTN 082 [50,55] among women, as indicated by high rates of IPV and STIs |
| STI prevalence are high among AGYW initiating PrEP | 30% prevalence of chlamydia and/or gonorrhoea in EMPOWER, POWER [78] and HPTN 082 [53] |
| Importance of PrEP education among influencers of young women (e.g., parents, partners) as they act often as detractors or supporters of PrEP use | We would meet with other participants and encourage each other during the adherence clubs that we did, we would encourage each other to take PrEP. HPTN 082 participant |
| Need to make PrEP access convenient and evaluate the feasibility of community-based delivery (i.e. existing points of contact with young women such as hairdressers, support groups, adherence clubs) | He [my partner] can even send me a WhatsApp message and ask whether I haven’t forgotten to take my pills. Then I would say that I haven’t forgotten I will take them. And maybe we are messaging each other and its ten past eight, and then I quickly get up and take them. So he also reminds me sometimes. HPTN 082 participant |

AGYW, Adolescent girls and young women; IPV, intimate partner violence; STI, sexually transmitted infection.
are being evaluated in the 3P project to determine whether incentives are effective to focus adolescents’ attention on immediate rewards, support pill-taking habit formation, and help overcome potential cognitive biases that make prevention behaviours particularly challenging [69,70].

3 | CONCLUSIONS

PrEP works, works for women, works when taken during periods of HIV exposure, and offers powerful protection for women who take PrEP. It is useful to consider the lessons from PrEP demonstration projects for African AGYW. Demand creation efforts have underscored the need for positive framing about PrEP that include empowerment messages to create interest, as well as the need for broader community awareness and support to overcome the unfamiliarity with PrEP and to reduce stigma associated with using antiretrovirals for prevention. From a clinical perspective, PrEP can be delivered in simple ways, even through peers as has been demonstrated in Thailand [71]. One of the greatest lessons from PrEP projects to date is how little is necessary to deliver it, and that only a subset of users may need more adherence support or frequent contact. Risk assessment and PrEP decision tools need to be evaluated as ways to operationalize prevention effective adherence, reduce provider burden and to augment provider counselling. Simpler models of PrEP delivery are being evaluated, including community-based refills and use of self-testing for HIV to expedite visits. Adherence clubs are being evaluated as a strategy to support PrEP persistence, similar to the model of community ART clubs have been demonstrated to be very acceptable and improve ART persistence and adherence among those living with HIV [72].

An important tension with simple, parsimonious PrEP delivery for African AGYW is that they have high rates of depression, IPV, and STIs, and ideally PrEP programmes should include wrap-around services for mental health and STIs. If PrEP programs are not able to address them directly, they must be prepared for them and have adequate referral sources in place. Given the remarkably high rates of asymptomatic curable bacterial STIs in young African women initiating PrEP, syndromic STI case management is inadequate and needs to be replaced with sensitive and affordable STI testing.

Health economic modelling is needed to define the minimal level of PrEP use at the individual level (based on their “seasons of risk”) and at a population level to have a public health impact. Given constrained resources, cost analyses and time-motion studies are needed of different facility-based, mobile and community-based PrEP delivery models. To estimate the health benefit of PrEP, prevention effective adherence will need to be balanced against the risk of HIV acquisition and the impact of PrEP delivery on health resources, which are the opportunity costs of delivering PrEP. Within a streamlined PrEP delivery model in a high HIV burden setting, PrEP use among persons at risk could reduce HIV incidence [73]. For moderate burden settings, mathematical models can project the incremental benefits and costs of PrEP in addition to, and, in comparison to other HIV prevention interventions. Data on real world uptake and use are needed here to guide program delivery. Integration of PrEP into platforms that provide health care, such as family planning services and STI testing, can share administrative costs thus decreasing the cost of PrEP delivery. Routine programme evaluation, including costing, can be used to estimate the cost of streamlined PrEP delivery within and outside facilities [74,75].

In summary, oral PrEP is a novel HIV prevention strategy which has high efficicacy when used consistently around the time of HIV exposure and about which we are learning about successful delivery. The early lessons from oral PrEP demonstration projects among African AGYW are relevant to longer-acting and less adherence-dependent HIV prevention formulations which are in development, including the dapivirine vaginal ring, injectable cabotegravir, and antiretroviral implants. Longer-acting PrEP formulations will be simpler for women to use but will also require demand creation, goal setting, risk assessment, adherence support, and simple delivery models in order to achieve the coverage needed to have a public health impact. As with the contraception field, it is important to provide women with a choice of products that meet their reproductive and HIV prevention needs and learn how to support their choice and facilitate their uptake and persistence during periods of high risk.

AUTHORS’ AFFILIATIONS

1 Department of Global Health, University of Washington, Seattle, WA, USA; 2 Department of Medicine, University of Washington, Seattle, WA, USA; 3 Department of Epidemiology, University of Washington, Seattle, WA, USA; 4 Wits Reproductive Health and HIV Institute, University of Witswatersrand, Johannesburg, South Africa; 5 RTI International, Women’s Global Health Imperative (WGHI) Program, San Francisco, CA, USA; 6 Department of Psychiatry, Stroger Hospital, Chicago, IL, USA; 7 Kenya Medical Research Institute, Nairobi, Kenya; 8 Departments of Obstetrics-Gynecology, University of Washington, Seattle, WA, USA; 9 Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 10 Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

COMPETING INTERESTS

Dr Celum received donations of Truvada from Gilead Inc for the conduct of research studies and scientific advisory fees from Merck outside the submitted work; Dr Delany-Moretwe has received a donation of Truvada for a research study; Dr. Baeten has received scientific advisory fees from Gilead and Merck outside the submitted work; Dr van der Straten received non-financial support from Gilead sciences outside the submitted work. Dr. Bekker reports non-financial support from Gilead and Merck outside the submitted work. Dr Hosek has received donations of Truvada for research studies.

AUTHORS’ CONTRIBUTIONS

CC designed and wrote the paper. SD-M, JB, AV-S, SH, EB, MM, RB and LGB contributed data, drafted sections of the manuscript and reviewed the final manuscript.

ACKNOWLEDGEMENTS

The authors acknowledge the invaluable contributions of the young African women who have participated in the PrEP efficacy trials and implementation projects, the efforts of the staff who implemented these studies, and the funding agencies which sponsored these studies.

FUNDING

Bill and Melinda Gates Foundation, OPP1161329 (Banbury Summits for Global Health and Development: HIV).

REFERENCES

1. UNAIDS. Global AIDS update. Miles to go: closing gaps, breaking barriers, righting injustices. Geneva: UNAIDS; 2018.
2. Baeten JM, Palenue-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in Africa. N Engl J Med. 2016;375(5):211–22.

3. Fonner VA, Dalgliesh SL, Kennedy CE, Baggaley R, O’Reilly KR, Korchin FM, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.

4. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):599–608.

5. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kagia S, et al. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.

6. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

7. Baeten JM, Donnell D, Ndase P, Mugy NR, Campbell JD, Wangsi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

8. Choopanya K, Martin M, Sunthararamai P, Sangkum U, Mock PA, Leethocharwali M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

9. Thippayya MC, Klabatbetse PW, Pointon LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.

10. Murnane PM, Celum C, Mugy NR, Campbell JD, Donnell D, Bukuvi E, et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(12):195–60.

11. Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, et al. Prevention of HIV-1 infection in women using oral pre-exposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73(5):606.

12. Argo N, Krishnamurti T, Fischhof B. Should I take PrEP? A mental models assessment of young African women’s motivations for and barriers to PrEP initiation and adherence. International AIDS Conference; July 23-27; Amsterdam, The Netherlands. 2018.

13. Corneli A, Perry B, Agot K, Ahmed K, Malamathfo F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS ONE. 2015;10(4):e0125458.

14. Katz A, Mensch B, Woeker K, Musara P, Etima J, van der Straten A. Understanding women’s motivations to participate in MTN-003/VOICE, an HIV prevention trial with low adherence. HIV Research for Prevention Conference (HRVP); October 17–20; Chicago, IL. 2016.

15. Macphail C, Delany-Morettle S, Mayaud P. “It’s not about money; it’s about my health”: determinants of participation and adherence among women in an HIV-HSV2 prevention trial in Johannesburg, South Africa. Patient Prefer Adherence. 2012;6:579–88.

16. Magazi B, Stadler J, Delany-Morettle S, Montgomery E, Mathewbu F, Hartmann M, et al. Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa. BMC Womens Health. 2014;14:88.

17. Corneli AL, McKenna K, Perry B, Ahmed K, Malamathfo F, et al. The science of being a study participant: FEM-PrEP participants’ explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015;68(5):578–84.

18. van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET. Perspectives on use of oral and vaginal antiretrovirals for HIV pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.

19. van der Straten A, Agot K, Weinrib R, Browne EN, Manenzhe K, et al. The tablets, ring, injections as options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21(3):e25094.

20. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.

21. Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong Y, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1:3.

22. Baeten J, Heffron R, Kidoguchi L, Mugy N, Katabra B, Bukuvi E, et al. Integrate-}

23. Linnemayer S. HIV prevention through the lens of behavioral economics. J Acquir Immune Defic Syndr. 2015;68(4):e1–3.
1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099.

45. Baeten J, Palanee-Philips T, Mgodi N, Mayo A, Neil A, Rosenberg Z, et al. High uptake and reduced HIV-1 incidence in an open-label, trial of the dapivirine ring. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7; Boston, MA; 2018.

46. Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2016;5 (2):e66–78.

47. Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 2017;171(11):1063–71.

48. World Health Organization. WHO implementation guidance for pre-exposure prophylaxis of HIV infection. Geneva, Switzerland: World Health Organiza-
tion; 2016.

49. Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. J Int AIDS Soc. 2017;20(1):21842.

50. Meyers L, Bekker L-G, Auinger R, van der Straten A, Morton J, McConnell M, et al. A behaviour-centered design approach to creating demand for oral PrEP among young women in Masiphumelele, South Africa. International AIDS Conference; July 23–27; Amsterdam, The Netherlands; 2018.

51. Wagner LD, Roberts S, O’Rourke S, Celum C, Baeten J, Bukusi E, et al. Challenges with oral pre-exposure prophylaxis (PrEP) disclosure among adolescent girls and young women (AGYW) in Kenya and South Africa. The HIV Research For Prevention Conference (HIVR4P); October 21-25; Madrid, Spain; 2018.

52. Celum C, Mgodi N, Bekker L-G, Hosek S, Donnell D, Anderson P, et al. Adherence 3 months after PrEP initiation among young African women in HPTN 082. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7; Seattle, WA; 2019.

53. Delany-Morettwe, Mgodi N, Bekker L-G, Baeten J, Pathak S, Donnell D, et al. High curable STI prevalence and incidence in HPTN 082. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7; Seattle, WA; 2019.

54. Rousseau-Jemwa E, Bekker L-G, Bukusi E, Delany-Morettwe S, Omololo V, Travell D, et al. Early persistence of HIV pre-exposure prophylaxis (PrEP) in African adolescent girls and young women (AGYW) from Kenya and South Africa. HIV Research for Prevention Meeting (HIVR4P); October 21-25; Madrid, Spain; 2018.

55. Celum C, Delany-Morettwe S, Hosek S, Dye B, Bekker L, Mgodi N, et al. Risk behavior, perception, and reasons for PrEP among young African women in HPTN 082. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7; Boston, MA; 2018.

56. Celum C, Gill K, Morton J, Stein G, van der Straten A, Baeten J, et al. High adherence among young women in Cape Town in the first 3 months after PrEP START. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7; Seattle, WA; 2019.

57. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52 (4):465–73.

58. Spiegel HM, Futterman DC. Adolescents and HIV: prevention and clinical care. Curr HIV/AIDS Rep. 2009;6(2):100–7.

59. Denison JA, Banda H, Dennis AC, Packer C, Nyambe N, Stalter RM, et al. "The sky is the limit": adhering to antiretroviral therapy and HIV self-management from the perspectives of adolescents living with HIV and their adult caregivers. J Int AIDS Soc. 2015;18(1):19358.

60. Massy M, Blaauw-Philips T, Vicior M, Judith B, Kweeza F, Snow RC, et al. Psychosocial challenges and strategies for coping with HIV among adolescents in Uganda: a qualitative study. AIDS Patient Care STDS. 2015;29 (2):66–94.

61. Sung-Hee K, Susan M, Samuel K, Caroline F, Sarah F. Importance of self-motivation and social support in medication adherence in HIV-infected adolescents in the United Kingdom and Ireland: a multicentre HYPLNet study. AIDS Patient Care STDS. 2015;29(6):354–64.

62. Fisher EB, Boothroyd RI, Coufal MM, Baumann LC, Mbanya JC, Rotheram-Borus MJ, et al. Peer support for self-management of diabetes improved outcomes in international settings. Health Aff. 2012;31(11):130–9.

63. Scrogie F, Stadler J, Baron D, Ju S, Ikaning T, Mulude Z, et al. "It was not my aim to sleep there": the impact of timing and location of sex on adherence to coital-dependent HIV pre-exposure prophylaxis. AIDS Behav. 2018;22 (11):3692–704.

64. Delany-Morettwe S, Lombard C, Baron D, Bekker L-G, Nkala B, Ahmed K, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-con-
trolled trial. Lancet Infect Dis. 2018;18(11):1241–50.

65. Mudhune S, Delany-Morettwe S, Baron D, Pato S, Stadler J, Ngcobo N, et al. Motivating, measuring and monitoring adherence in the FACTS 001 tenofo-
vir gel microbicide study. HIV Research For Prevention Conference (HIVR4P); October 27-31; Cape Town, South Africa; 2014.

66. Ramskin L, Baron D, Makgamathe K, Schutzman J, Stangl A, Sievwright K, et al. EMPOWER clubs for young women using oral PrEP as part of an HIV pre-
vention package: what we have learned so far. Adherence to HIV prevention and treatment. Adherence to HIV Prevention and Treatment; April 26-27; Harare, Zimbabwe; 2018.

67. Mani A, Mullainathan S, Shafir E, Zhao J. Poverty impedes cognitive func-
tion. Science. 2013;341(6149):976–80.

68. Linneman S, Stecher C, Mukasa B. Behavioral economic incentives to improve adherence to antiretroviral medication. AIDS. 2017;31(5):719–26.

69. Dupas P. Health behavior in developing countries. Annu Rev Econ. 2011;3(1):425–49.

70. Loewenstein G, Price J, Volpp K. Habit formation in children: evidence from incentives for healthy eating. J Health Econ. 2016;45:47–54.

71. VannakR, Kim M, Charoenying S, Mills S, Avery M, Phanuphak PN, et al. Key population-led health services (KP-LHS) critical to PrEP introduction among MSM and TG in Thailand. International AIDS Conference; July 23–27; Amster-
dam, The Netherlands; 2018.

72. Tsandl PR, Wilkinson LS, Grimsrud A, Mdlalo PT, Ullauri A, Boule A. High rates of retention and viral suppression in the scale-up of antiretroviral therapy adherence clubs in Cape Town, South Africa. J Int AIDS Soc. 2017;20 Supp1 42:169.

73. McGillen JB, Anderson SJ, Hallett TB. PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. J Int AIDS Soc. 2016;19(6 Supp1):21104.

74. Peebles K, Mugwanya K, Irungu E, Odoyo J, Wamoni E, Morton J, et al. Low costs and opportunities for efficiency in the first year of programmatic PrEP delivery in Kenya’s Public Sector. HIV Research for Prevention Conference (HIVR4P); October 21-25; Madrid, Spain; 2018.

75. Roberts A. The role of costing in the introduction and scale up of pre-expo-
sure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya. J Int AIDS Soc. Submitted.

76. Gill K. Evaluation of PrEP demand creation and uptake among young women in a Cape Town township: the 3P study. International AIDS Conference; July 23-27; Amsterdam, The Netherlands; 2018.

77. Rousseau-Jemwa E, Celum C, Baeten J, Bekker L-G. A comparative study of risk among adolescent girls and young women who accept or decline PrEP uptake from a community-based mobile clinic. International AIDS Conference; July 23-27; Amsterdam, The Netherlands; 2018.

78. Morton J, Bukusi E, Delany-Morettwe S, Bekker L-G, Omololo V, Travill D, et al. High prevalence of curable STIs among young women initiating PrEP in Kenya and South Africa. International AIDS Conference; July 23-27; Amsterdam, The Netherlands; 2018.